Mal-PEG1-Val-Cit-OH is a maleimide-based ADC linker with PEG spacer and Val-Cit dipeptide for enzymatic cleavage. Ideal for stable antibody conjugation and targeted payload release in antibody-drug conjugate development.
Structure of
* For research and manufacturing use only. We do not sell to patients.
Size | Price | Stock | Quantity |
---|---|---|---|
-- | $-- | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
Mal-PEG1-Val-Cit-OH, a versatile chemical linker essential in bioconjugation and drug development, finds diverse applications in various fields.
Antibody-Drug Conjugates (ADCs): Mal-PEG1-Val-Cit-OH plays a crucial role in the synthesis of antibody-drug conjugates, innovative cancer treatments that merge antibody specificity with potent cytotoxic drugs. This chemical serves as a robust linker that ensures controlled drug release specifically within the tumor microenvironment, enhancing the therapeutic efficacy of ADCs while minimizing harm to healthy tissues. The intricate interplay between antibodies and cytotoxic drugs mediated by Mal-PEG1-Val-Cit-OH underscores the precision of targeted cancer therapies.
Protein-Protein Conjugation: Within protein engineering, Mal-PEG1-Val-Cit-OH functions as a cross-linker, facilitating the connection between proteins or peptides for studying protein interactions and functions. This application is indispensable for generating complex biomolecules utilized in diagnostics and therapeutics. Through the strategic modification of proteins using this linker, researchers can bolster protein stability and activity while finely tuning their biological interactions. The versatile nature of Mal-PEG1-Val-Cit-OH in protein-protein conjugation underscores its significance in advancing biotechnological research.
Nanoparticle Functionalization: In the domain of nanotechnology, Mal-PEG1-Val-Cit-OH is instrumental in nanoparticle functionalization, enabling targeted delivery and controlled release of therapeutic agents. This capability is pivotal in constructing nanocarriers for drug delivery systems aimed at enhancing drug solubility and bioavailability. The inherent biocompatibility of Mal-PEG1-Val-Cit-OH ensures the stability of nanoparticles within biological environments, elevating their therapeutic effectiveness significantly.
Controlled Drug Release Systems: In the realm of pharmaceuticals, the adoption of Mal-PEG1-Val-Cit-OH in controlled drug delivery systems offers a method of tethering drugs to polymers or carriers for regulated drug release in response to specific stimuli like pH or enzymatic activity. This sophisticated mechanism ensures localized drug delivery precisely at the target site, enhancing treatment efficacy while reducing adverse effects.
Catalog | Product Name | CAS | Inquiry |
---|---|---|---|
BADC-00442 | Mal-PEG6-NHS | 1137109-21-7 | |
BADC-00448 | Mal-PEG-NHS | 1260092-50-9 | |
BADC-00443 | Mal-PEG5-NHS | 1315355-92-0 | |
BADC-00450 | Mal-PEG4-NHS | 1325208-25-0 | |
BADC-01679 | Mal-PEG2-Val-Cit-PABA-PNP | 1345681-52-8 | |
BADC-00936 | Mal-PEG2-acid | 1374666-32-6 | |
BADC-00449 | Mal-PEG4-PFP | 1415800-42-8 | |
BADC-00453 | Mal-PEG2-NHS ester | 1433997-01-3 | |
BADC-00603 | Mal-PEG3-NHS ester | 1537892-36-6 | |
BADC-00966 | Mal-PEG4-VC-PAB-DMEA | 1569261-93-3 |
Contact our experts today for pricing and comprehensive details on our ADC offerings.
From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.
Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.
Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.